

NANOFORM EXPANDS COMMERCIAL PRESENCE IN ASIA WITH A&LS PHARMA IN SOUTH KOREA

Nanoform Finland Plc | Press Release | September 30, 2025 at 09:30:00 EEST

Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced it has entered into a distributor agreement with Ageing & Life Science Corp. ("A&LS"), a South Korean pharmaceutical products and services distribution company based in Seoul, South Korea, to bring Nanoform's cutting-edge nanomedicines and technologies to the country's pharmaceutical and biotech market.

Under the agreement, A&LS will act as Nanoform's partner in South Korea, supporting local pharmaceutical and biotech innovators to access Nanoform's proprietary nanoparticle engineering services for both small and large molecules.

"We are thrilled to extend our Asian presence into South Korea, which is home to one of the world's most dynamic and innovation-driven life science markets supported by significant government investment, a strong domestic pharmaceutical base, world-class biologics manufacturing capacity, and an active clinical trial ecosystem," commented Christian Jones, Chief Commercial Officer of Nanoform. "This environment creates unique opportunities for Nanoform to support companies in improving bioavailability, enhancing patient convenience and accelerating the development of next-generation therapies. Partnering with A&LS will build on Nanoform's momentum in Japan and positions us to support a new wave of Korean innovators seeking to differentiate their products through our nanotechnology."

Mr Won-Mook (William) Kim, President of A&LS Pharma, added, "Nanoform's unique nanoparticle engineering services perfectly complement our mission to bring advanced solutions to Korean pharmaceutical and biotech clients. We look forward to helping our customers unlock the full potential of their molecules and deliver better medicines to patients."

According to research, pharmaceutical market revenue in South Korea was valued at USD 28.83 billion in 2024 and is forecast grow at 7.4% (CAGR) between 2025 and 2030, to reach USD 44.25 billion. ^[1]

[1] Grand View Horizon *South Korea Pharmaceutical Market Size & Outlook* available at <https://www.grandviewresearch.com/horizon/outlook/pharmaceutical-market/south-korea>

For further information, please contact:

Christian Jones, Chief Commercial Officer

Christian.jones@nanoform.com

+44 (0)7804 474 771

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com

+46 (0)7686 650 11

About Nanoform

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@carnegie.se. For more information, please visit www.nanoform.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words "may", "will", "could", "would", "should", "expect", "plan", "anticipate", "intend", "believe", "estimate", "predict", "project", "potential", "continue", "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2024 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Attachments

NANOFORM EXPANDS COMMERCIAL PRESENCE IN ASIA WITH A&LS PHARMA IN SOUTH KOREA